Evidence map›Paper›PMID 25941577›Full record

ReviewOncoimmunology2014

Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells.

Sarah K Maenhout, Kris Thielemans, Joeri L Aerts

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sarah K MaenhoutLaboratory of Molecular and Cellular Therapy; Department of Immunology-Physiology ; Vrije Universiteit Brussel ; Brussels, Belgium.
Kris ThielemansLaboratory of Molecular and Cellular Therapy; Department of Immunology-Physiology ; Vrije Universiteit Brussel ; Brussels, Belgium.
Joeri L AertsLaboratory of Molecular and Cellular Therapy; Department of Immunology-Physiology ; Vrije Universiteit Brussel ; Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An increasing number of studies is focusing on the role of myeloid-derived suppressor cells (MDSCs) in the suppression of antitumor immune responses. Although the main site of action for MDSCs is most likely the tumor microenvironment, the study of these cells has been largely restricted to MDSCs derived from peripheral lymphoid organs. Only in a minority of studies MDSCs isolated from the tumor microenvironment have been characterized. This review will give an overview of the data available on the phenotypical and functional differences between tumor-derived MDSCs and MDSCs isolated from the spleen of tumor-bearing mice or from the peripheral blood of cancer patients.

Indexed as

ATRA, all-trans retinoic acidBv8, Bombina variagata peptide 8CTLA-4, cytotoxic T-lymphocyte antigen-4GM-CSF, granulocyte-macrophage colony-stimulating factorIFN-γ, interferon gammaIL-4Rα, interleukin-4 receptor alphaIL, interleukinimmunosuppressioniNOS, inducible nitric oxide synthaseLPS, lipopolysaccharideMAPK, mitogen-activated protein kinasesM-CSF, macrophage-colony stimulating factorMDSCs, myeloid-derived suppressor cellsmyeloid-derived suppressor cellsNS cells, natural suppressor cellsPD-L1, programmed death-ligand 1PHA, phytohemagglutininROS, reactive oxygen speciessiRNA, small interfering ribonucleic acidTAMs, tumor-associated macrophagesTreg, regulatory T cellstumor immunologytumor microenvironmenttumor modelsVEGF, vascular endothelial growth factor.

Identifiers

PMID25941577
PMCPMC4292540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.